Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study

Bermejo-Martín, Jesús F.; García-Mateo, Nadia; Motos, Anna; Resino, Salvador; Tamayo, Luís; Murúa, Pablo Ryan; Bustamante-Munguira, Elena; Curto, Elena; Úbeda-Iglesias, A.; Torre, María del Carmen de la; Estella, Ángel; Campos-Fernández, Sandra; Varela, Ignacio Martínez; Pérez-García, Felipe; Socías, Lorenzo; Messa, Juan López; Vidal-Cortés, Pablo; Meneses, Víctor Sagredo; González-Rivera, Milagros; Carbonell, Nieves; Gonzalo‐Calvo, David de; Delgado, M.C. Martín; Valdivia, Luis Jorge; Martín-López, Caridad; García, Ruth Noemí Jorge; Maseda, Emilio; Loza-Vázquez, Ana; Kelvin, David J.; Barbé, Ferrán; Torres, Antoni; Ortega, Alicia; Fuente, Amanda de la; Almansa, Raquel; Postigo, Tamara; Jorge, Noelia; Tedim, Ana P.; González-González, Laura; Recio, Lara Sánchez; Trapiello, Wysali; Berezo, José Ángel; Herrán-Monge, Rubén; Blanco, Jesús; Enríquez, Pedro; Martı́nez, Isidoro; Martín-Vicente, María; Muñoz-Gómez, María José; Más, Vicente; Vázquez, Mónica; Cano, Olga; Gándara, Amalia Martínez de la; Rodrı́guez, Covadonga; Andrade, Gloria; Renedo, Gloria; Bustamante‐Munguira, Juan; Ávila, Ramón Cicuendez; Salgado-Villén, María; Berruguilla-Pérez, Enrique; Güell, Estel; Monachello, Fernando Javier Casadiego; Núñez, María Recuerda; Calvo, Juan Manuel Sánchez; Peñasco-Martín, Yhivian; Unzueta, Marı́a Teresa Garcı́a; Ceccato, Adrián; Fernández-Barat, Laia; Vieiro, María Teresa Bouza; Moreno-Romero, Ana; Bastida, Leire Pérez; Río-Carbajo, Lorena del; Martínez, Noelia Albalá; Gómez, José Manuel Naranjo; Blasco, María Luisa; Caballero, Jesús; Barberà, Carme; González, Jessica; Nieto, María Teresa García; Olmo, Jorge Nieto-del; Prol-Silva, Estefanía; Canseco-Ribas, Joan; Eirós, José María

doi:10.1016/s2666-5247(23)00041-1

Cited by 13 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, these pathogens might play an important role in the disease manifestation of the respiratory tract and blood, followed by primary infection, and therefore should be taken into account when studying coinfection and super-infection [ 34 , 35 ]. For example, herpesvirus coinfection, particularly with HSV-1, is thought to be associated with severe respiratory infections [ 36 ]. Herpesvirus coinfection may cause orolabial herpes to reactivate and progress into pulmonary or tracheal infection, resulting in infiltrated inflammatory cells in lung necrosis, alveolar hemorrhage, and parenchyma and leading to severe disease [ 5 , 37 , 38 ].…”

Section: Discussionmentioning

confidence: 99%

Total Infectome Characterization of Respiratory Infections during the 2022–23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity

Yang,

Cai,

Liao

et al. 2024

Pathogens

View full text Add to dashboard Cite

Between December 7th 2022 and February 28th 2023, China experienced a new wave of COVID-19 that swept across the entire country and resulted in an increasing amount of respiratory infections and hospitalizations. The purpose of this study is to reveal the intensity and composition of coinfecting microbial agents. In total, 196 inpatients were recruited from The Third People's Hospital of Shenzhen, and 169 respiratory and 73 blood samples were collected for metagenomic next-generation sequencing. The total “Infectome” was characterized and compared across different groups defined by the SARS-CoV-2 detection status, age groups, and severity of disease. Our results revealed a total of 22 species of pathogenic microbes (4 viruses, 13 bacteria, and 5 fungi), and more were discovered in the respiratory tract than in blood. The diversity of the total infectome was highly distinguished between respiratory and blood samples, and it was generally higher in patients that were SARS-CoV-2-positive, older in age, and with more severe disease. At the individual pathogen level, HSV-1 seemed to be the major contributor to these differences observed in the overall comparisons. Collectively, this study reveals the highly complex respiratory infectome and high-intensity coinfection in patients admitted to the hospital during the period of the 2023 COVID-19 pandemic in China.

show abstract

Section: Discussionmentioning

confidence: 99%

Total Infectome Characterization of Respiratory Infections during the 2022–23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity

Yang,

Cai,

Liao

et al. 2024

Pathogens

View full text Add to dashboard Cite

show abstract

“…We should consider also that hyper-inflammation is not the only factor contributing to disease severity and mortality in COVID-19 infected patients. A recently published study shows that patients admitted to the intensive care unit with a high release of viral components to the circulation (“viral storm”) have higher mortality than those with lower viral load ( Bermejo-Martin et al, 2023 ). Indeed, antiviral drugs and monoclonal antibodies demonstrated to reduce the risk of hospitalization and death when given during the first days since symptoms onset ( Akinosoglou et al, 2023 ; Saravolatz et al, 2023 ).…”

Section: Discussionmentioning

confidence: 99%

Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes: an unCoVer analysis

Salvador,

Mazzi,

De Santis

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Effective domiciliary treatment can be useful in the early phase of COVID-19 to limit disease progression, and pressure on hospitals. There are discrepant data on the use of non-steroidal anti-inflammatory drugs (NSAIDs). Aim of this study is to evaluate whether the clinical outcome of patients who were hospitalized for COVID-19 is influenced by domiciliary treatment with NSAIDs. Secondary objective was to explore the association between other patient characteristics/therapies and outcome.Methods: A large dataset of COVID-19 patients was created in the context of a European Union-funded project (unCoVer). The primary outcome was explored using a study level random effects meta-analysis for binary (multivariate logistic regression models) outcomes adjusted for selected factors, including demographics and other comorbidities.Results: 218 out of 1,144 patients reported use of NSAIDs before admission. No association between NSAIDs use and clinical outcome was found (unadj. OR: 0.96, 95%CI: 0.68-1.38). The model showed an independent upward risk of death with increasing age (OR 1.06; 95% CI 1.05-1.07) and male sex (1.36; 95% CI 1.04-1.76).Conclusion: In our study, the domiciliary use of NSAIDs did not show association with clinical outcome in patients hospitalized with COVID-19. Older ages and male sex were associated to an increased risk of death.

show abstract

“…ET-1 levels were also significantly higher in patients suffering from complications such as acute kidney and myocardial injury, and death. Furthermore, patients with higher viral levels, which were associated with more severe disease and an increase in all-cause death, had higher ET-1 plasma levels than those patients with lower viral loads [110].…”

Section: Covid-19mentioning

confidence: 92%

“…Early hypertension [95] Hypertension [95,96] Malignant hypertension [96,97] Atherosclerosis [98][99][100][101][102] ↑ Cardiac ischaemia [103] Plasma ET-1 levels Air pollution-induced vascular pathology [104,105] Asthma [106] Rheumatoid arthritis [107] COVID-19 [108][109][110] No change…”

Section: Changes To Et-1 Pathway Associated Pathology Referencementioning

confidence: 99%

Endothelin-1 in Health and Disease

Banecki

Dora

2023

IJMS

View full text Add to dashboard Cite

Discovered almost 40 years ago, the potent vasoconstrictor peptide endothelin-1 (ET-1) has a wide range of roles both physiologically and pathologically. In recent years, there has been a focus on the contribution of ET-1 to disease. This has led to the development of various ET receptor antagonists, some of which are approved for the treatment of pulmonary arterial hypertension, while clinical trials for other diseases have been numerous yet, for the most part, unsuccessful. However, given the vast physiological impact of ET-1, it is both surprising and disappointing that therapeutics targeting the ET-1 pathway remain limited. Strategies aimed at the pathways influencing the synthesis and release of ET-1 could provide new therapeutic avenues, yet research using cultured cells in vitro has had little follow up in intact ex vivo and in vivo preparations. This article summarises what is currently known about the synthesis, storage and release of ET-1 as well as the role of ET-1 in several diseases including cardiovascular diseases, COVID-19 and chronic pain. Unravelling the ET-1 pathway and identifying therapeutic targets has the potential to treat many diseases whether through disease prevention, slowing disease progression or reversing pathology.

show abstract

Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study

Cited by 13 publications

References 29 publications

Total Infectome Characterization of Respiratory Infections during the 2022–23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity

Total Infectome Characterization of Respiratory Infections during the 2022–23 COVID-19 Outbreak in China Revealed Extensive Coinfections with Links to SARS-CoV-2 Status, Age, and Disease Severity

Impact of domiciliary administration of NSAIDs on COVID-19 hospital outcomes: an unCoVer analysis

Endothelin-1 in Health and Disease

Contact Info

Product

Resources

About